- Previous Close
0.9273 - Open
0.9000 - Bid --
- Ask 0.9303 x 100
- Day's Range
0.7301 - 1.0200 - 52 Week Range
0.6300 - 3.2300 - Volume
222,694 - Avg. Volume
64,720 - Market Cap (intraday)
27.486M - Beta (5Y Monthly) 0.41
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.00
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.
www.estrellabio.comRecent News: ESLA
View MorePerformance Overview: ESLA
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ESLA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ESLA
View MoreValuation Measures
Market Cap
27.49M
Enterprise Value
5.65M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
191.23
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-8.85M
Diluted EPS (ttm)
-0.2400
Balance Sheet and Cash Flow
Total Cash (mrq)
1.8M
Total Debt/Equity (mrq)
0.54%
Levered Free Cash Flow (ttm)
--